Harbor Capital Advisors’s Utah Medical Products UTMD Stock Holding History

Harbor Capital Advisors’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$24K	Buy	328 +270	+466%	+$19.2K	﹤0.01%	940
2026 Q2	$4K	Sell	58 -120	-67%	-$7.98K	﹤0.01%	1170
2026 Q1	$11K	Buy	178 +148	+493%	+$9.32K	﹤0.01%	963
2025 Q4	$2K	Sell	30 -1	-3%	-$58	﹤0.01%	1291
2025 Q3	$2K	Sell	31 -52	-63%	-$3.08K	﹤0.01%	1310
2025 Q2	$5K	Sell	83 -6	-7%	-$326	﹤0.01%	1191
2025 Q1	$5K	Hold	89	–	–	﹤0.01%	1215
2024 Q4	$5K	Sell	89 -2	-2%	-$129	﹤0.01%	1149
2024 Q3	$6K	Buy	+91	New	+$6.18K	﹤0.01%	1109

Other funds holding UTMD

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Cardinal Capital Management Inc (North Carolina) Raleigh, North Carolina $861M AUM 27.19% 1-Year Est. Return

O'Shaughnessy Asset Management Stamford, Connecticut $23.6B AUM 34.05% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.46B AUM 13.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Harbor Capital Advisors's UTMD Position: Q3 2026 in Review

Harbor Capital Advisors increased its Utah Medical Products (UTMD) stake by 466% in Q3 2026, buying an estimated $19.2K and bringing the position to 328 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #940.

Harbor Capital Advisors first reported a position in UTMD in Q3 2024 and has held it in 9 quarters since. 74 funds tracked by Wall St. Rank hold UTMD as of Q3 2026.

Harbor Capital Advisors held 328 shares of Utah Medical Products worth $24K as of Q3 2026.
Harbor Capital Advisors bought 270 Utah Medical Products shares in Q3 2026, an estimated $19.2K.
Utah Medical Products made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q3 2026, its #940 holding.
Harbor Capital Advisors first reported a position in Utah Medical Products in Q3 2024 and has held it in 9 quarters since.
74 funds tracked by Wall St. Rank held Utah Medical Products as of Q3 2026.

Based on Harbor Capital Advisors's 13F filing for Q3 2026, filed 22 Oct 2026.